drugset
drugset / Trial / NCT03772340

Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness

NCT03772340 ↗

Phase 2 Completed 126 enrolled Vanda Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Randomized, double-blind, placebo-controlled investigating the efficacy of tradipitant in the treatment of motion sickness.

Timeline

Start
2018-12-20
Primary completion
2019-06-06
Completion
2019-06-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Tradipitant Small molecule — Oral

Indications

motion sickness